Want to see JP:6190 full AI Analyst Report?

PhoenixBio Co., Ltd. (6190) Price & Analysis

0 Followers

6190 Stock Chart & Stats

¥484.00

¥9.00(2.79%)

At close: Jan 08 4:00 PM EST

¥484.00

¥9.00(2.79%)

Day’s Range― - ―

52-Week Range¥321.00 - ¥724.00

Previous CloseN/A

Volume3.50K

Average Volume (3M)360.67K

Market Cap

¥1.44B

Enterprise Value¥1.13K

Total Cash (Recent Filing)¥1.15B

Total Debt (Recent Filing)¥486.64M

Price to Earnings (P/E)11.4

Beta0.53

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)30.80

Shares Outstanding4,076,933

10 Day Avg. Volume91,460

30 Day Avg. Volume360,670

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.14

P/FCF Ratio31.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary PXB-mouse PlatformPhoenixBio’s PXB humanized‑liver mouse models represent a structural competitive moat. The specialized biological model has high technical barriers, driving repeat engagements, enabling recurring project revenue and differentiated service offerings that support long‑term client stickiness.

High Gross MarginsA ~76% gross margin indicates durable pricing power and efficient service delivery for laboratory‑intensive CRO work. High gross profitability gives the company room to absorb SG&A or R&D, fund platform improvements, and sustain net profitability through revenue cycles.

Improving Leverage And ROELower leverage and a return to positive ROE (~8%) reflect an improving capital structure and reduced financial risk. Better leverage supports financing flexibility for capacity investments, lowers refinancing pressure, and strengthens resilience to cyclicality in preclinical demand.

Bears Say

Inconsistent Cash GenerationRepeated negative operating and free cash flow in prior years, and weak cash conversion even after a 2026 uptick, constrains the firm’s ability to self‑fund growth or cushion downturns. Reliance on external capital or working capital management increases financing and execution risk.

Multi-year Earnings VolatilityEarnings and margins have swung materially across years, undermining predictability for customers and investors. This volatility complicates multi‑year planning, weakens confidence in recurring revenue trajectories, and raises execution risk when scaling laboratory capacity or new services.

Small Scale / Capacity LimitsA small workforce (55 employees) suggests limited throughput and operational redundancy. Smaller scale can make scaling expensive, heighten sensitivity to key staff or single large projects, and constrain the ability to diversify client mix versus larger CRO competitors over the medium term.

6190 FAQ

What was PhoenixBio Co., Ltd.’s price range in the past 12 months?

PhoenixBio Co., Ltd. lowest stock price was ¥321.00 and its highest was ¥724.00 in the past 12 months.

What is PhoenixBio Co., Ltd.’s market cap?

PhoenixBio Co., Ltd.’s market cap is ¥1.44B.

When is PhoenixBio Co., Ltd.’s upcoming earnings report date?

PhoenixBio Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 95 days.

How were PhoenixBio Co., Ltd.’s earnings last quarter?

PhoenixBio Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -¥22.378 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is PhoenixBio Co., Ltd. overvalued?

According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PhoenixBio Co., Ltd. pay dividends?

PhoenixBio Co., Ltd. does not currently pay dividends.

What is PhoenixBio Co., Ltd.’s EPS estimate?

PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PhoenixBio Co., Ltd. have?

PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.

What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?

PhoenixBio Co., Ltd. reported an EPS of -¥22.378 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.284%.

Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?

Currently, no hedge funds are holding shares in JP:6190

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.